Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.



Aug 1, 2018 18:35 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Yidan Prize Conference Series: The Americas sets an outlook for innovation and evidence-based research in education  
May 24, 2019 17:00 HKT/SGT
Mitsubishi Motors Eclipse Cross Wins a String of Prestigious Awards in Russia  
May 24, 2019 16:35 HKT/SGT
Toyota Yaris WRC Tackles a Tough Gravel Double  
May 24, 2019 16:02 HKT/SGT
Sanli achieves revenue of S$71.4 million in FY2019  
May 24, 2019 10:00 HKT/SGT
WARC Media Awards 2019 open for entries  
May 23, 2019 22:00 HKT/SGT
Sanli achieves revenue of S$71.4 million in FY2019  
May 23, 2019 20:00 HKT/SGT
DENSO to Mass-produce Automotive Alternators Equipped with Newly Developed High-efficiency Diodes  
May 23, 2019 17:19 HKT/SGT
Tohoku University and DOCOMO Launch Research Project to Develop Artificial-intelligence Technology for Periodontal Disease Detection  
May 23, 2019 15:29 HKT/SGT
MHPS Receives Contract for Complete Renovation of Flue Gas Desulfurization System at the Dětmarovice Power Station in the Czech Republic  
May 23, 2019 14:15 HKT/SGT
The University of Tokyo, Toyota, and TRENDE to Begin Testing of Next-generation Electricity System  
May 23, 2019 13:03 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: